Lancet 1987,1(8547):1398–1402.PubMed 13. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995,19(3):183–232.PubMedCrossRef 14. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M:

Abemaciclib molecular weight Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat 2013,140(1):23–33.PubMedCrossRef 15. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M: EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer TSA HDAC chemical structure cells. J Exp Clin Cancer Res 2013.,32(70): doi:10.1186/1756–9966–32–70 doi:10.1186/1756-9966-32-70 16. Hickinson M, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Selleck GNS-1480 Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D: AZD8931, an equipotent,

reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB3 receptor blockade in cancer. Clin Cancer Res 2010,16(4):1159–1169.PubMedCrossRef 17. Burness ML, Grushko TA, Olopade OI: Epidermal growth factor receptor in triple-negative

and basal-like breast cancer: promising clinical target or only a marker? Cancer J 2010,16(1):23–32.PubMedCrossRef 18. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson GBA3 JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007,109(1):25–32.PubMedCrossRef 19. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989,43(2):201–208.PubMedCrossRef 20. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA: Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 2011,16(12):1675–1683.PubMedCentralPubMedCrossRef 21. Masuda H, Zhang DW, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT: Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012,136(2):331–345.PubMedCrossRef 22. Eccles SA: The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011,55(7–9):685–696.PubMedCrossRef 23.